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ORIGINAL ARTICLE

Insulinlike Growth Factor 1– and 2–Augmented
Collagen Gel Repair of Facial Osseous Defects
James S. Toung, BA; Roy C. Ogle, PhD; Raymond F. Morgan, DDS, MD; William H. Lindsey, MD

Background: Defects of the facial bone structure are

common problems for the facial plastic surgeon. Native
type 1 collagen gels (T1CGs) have been shown to mediate repair of facial critical-size defects in rat models.
Objective: To evaluate the efficacy of T1CG augmented with insulinlike growth factor (IGF) 1, IGF-2,
and a combination of IGF-1 and IGF-2 on the repair of
facial critical-size defects in a rodent model.
Methods: Twenty-four retired male breeder SpragueDawley rats were divided into 4 groups of 6 animals. Facial critical-size defects were created by removing the nasalis bones with a bone-cutting drill. Defects were treated
with 300 µg of type 1 collagen gel (T1CG), T1CG augmented with 3 µg of IGF-1, T1CG augmented with 3 µg
of IGF-2, or T1CG augmented with a combination of 3
µg of IGF-1 and 3 µg of IGF-2. After 30 days the animals
were examined at necropsy with precise planimetry, histological analysis of new bone growth, and radiodensi-
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tometric analysis of bone thickness.
Results: Radiodensitometric measurements showed that
IGF-2 augmentation resulted in greatest osseous healing, with measurements being statistically significant over
those of all other groups (P#.03). Combination IGF-1
and IGF-2 had osseous healing that was intermediate between IGF-1 augmentation and IGF-2 augmentation
alone, with measurements being statistically significant
over those of unaugmented gels (P,.001) and IGF-1 augmentation (P#.03). Augmentation with IGF-1 resulted
in healing that was significant over that of unaugmented gels (P#.04).
Conclusion: Collagen gels augmented with IGF signifi-

cantly enhance the osteoconductive repair of nasal criticalsize defects in a rodent model, with IGF-2 showing highest efficacy.
Arch Otolaryngol Head Neck Surg. 1999;125:451-455

SSEOUS DEFECTS of the na-

salis and other facial
bones can result from
many processes, including congenital malformations, trauma, neoplasms, and infections.
Current techniques for the repair of such
defects have major limitations or risks. Autogenous bone grafts using the iliac crest
or calvaria as a donor site are widely used
in reconstructive surgery; however, the
amount of graft material that can be obtained is limited and such techniques have
risks of donor site morbidity.1 Cadaveric
or allogenic bone is also available for grafts,
but there may be the potential for transferring viral pathogens.2 Demineralized
bone does promote bone repair but has unpredictable resorption rates, which may be
influenced by local vasculature, inflammation, and poor HLA match between host
and donor.3 Alloplastic materials such as
Silastic and silicone can be displaced and
can foster infections.

Critical-size defects (CSDs) are osseous defects that show less than 10% healing in 6 months or within the life of the
animal.4 With a CSD, bone regeneration
would only take place in the presence of
materials that are osteogenic. A CSD therefore provides a simple model for evaluating the osteogenic capabilities of materials and methods used in bone repair,
without the intervening variables found in
models that prevent osseous union by inhibiting the healing process. The rat nasal defect fulfills criteria to be used as a
CSD.5 Type 1 collagen gels (T1CGs) have
previously been shown to mediate the total surface repair of osseous nasal CSDs in
Sprague-Dawley rats.6
Insulinlike growth factors (IGFs)
have been shown to promote proliferation and protein synthesis in osteoblasts
and are believed to be the route by which
growth hormone mediates the growth of
bone. Thaller et al7 demonstrated that
supplying IGF-1 systemically through an
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MATERIALS AND METHODS
Twenty-four 6-month-old, retired male breeder SpragueDawley rats (450-500 g) were randomly assigned to 4 groups
of 6 rats to receive collagen (group 1), collagen plus IGF-1
(group 2), collagen plus IGF-2 (group 3), and collagen plus
IGF-1 plus IGF-2 (group 4).
All underwent an operative procedure to produce a CSD
as described previously.5 Animals were anesthetized with pentobarbital sodium, 17 mg/kg, and 10 mg of ketamine hydrochloride. The hair over the nose and frontal skull was shaved
and treated with a depilatory agent. The head was placed in
a cephalostat and the skin was incised from the nasal tip to
the supraorbital glabella. The periosteum was incised and
separated from the underlying bone for lateral retraction. With
the use of a bone-cutting burr with a handheld drill, the nasalis bones were removed and a rectangular defect measuring 5 3 15 mm was created. The floor of this defect was the
deep side of the superior nasal mucosal membranes. A diamond burr was used to shape the defect to the precise measurements. The nasal cavity was not violated. Copious saline irrigation was used to remove bone dust and debris. After
the defect was created and cleaned of debris, a collagen gel
(with or without IGF augmentation) was placed into the defect. The periosteum was closed with a 6-0 nylon suture. The
skin was closed with 4-0 polypropylene. After recovery from
anesthesia, the animals were returned to the vivarium for routine housing.
Thirty days after surgery, the rats were killed by intracardiac lidocaine injection. The entire nasal dorsum of each
rat was removed by using a cutting burr and was cleaned.
The defects then underwent radiography (Faxitron

osmotic infusion pump accelerated the repair of calvarial CSDs in rats.7 It was also previously shown that
3-dimensional T1CGs augmented with IGF-1 result in
significantly increased healing over that of unaugmented collagen gels (P,.04).8 Fewer studies have
been conducted on the effects of IGF-2; however, in
vitro studies on bone cell cultures seem to indicate that
IGF-2 and IGF-1 have the same efficacy in stimulating
protein synthesis but that higher levels of IGF-2 are
necessary to achieve the same effects, indicating that
IGF-2 has less potency.9 This study used a nasal CSD to
determine the effect of 3-dimensional T1CGs augmented with IGF-2 and combination IGF-1 and IGF-2
on the repair of endochondral bone defects.
RESULTS

At necropsy, samples from all groups grossly appeared
to have total surface healing, with the samples from the
augmented groups appearing grossly thicker than samples
of the unaugmented group. Bone densities and thicknesses of the excised nasal dorsums were compared by
means of radiodensitometric values as explained previously.8 Briefly, the samples were x-rayed and the developed films scanned into a computer. ImageQuant converts the radiopacity from the scanned x-ray image into
arbitrary volume units, with greater radiopacity corre-

Series model 43085N; Hewlett-Packard, Palo Alto, Calif) with
an exposure time of 30 seconds at 30 kV (X-OMAT-AR film;
Eastman Kodak Co, Rochester, NY). The developed x-ray
films were then scanned into a computer by means of a densitometer (Molecular Dynamics Personal Densitometer; Molecular Dynamics, Sunnyvale, Calif), and the radiodensity
of the defects was quantified with ImageQuant NT version
4.3 software (Molecular Dynamics). The defects were then
treated with decalcifying solution (J. T. Baxter Inc, Deerfield, Ill) and embedded into paraffin for sectioning and hematoxylin-eosin staining to histologically evaluate new bone
growth.
Rat tail collagen was prepared as previously described.6,10 Rat tail collagen (2.8 mg/mL) in ice-cold 0.5mol/L acetic acid was dialyzed against unbuffered Dulbecco modified Eagle medium and sterilized by addition of
0.1% chloroform during dialysis. To form gels, type 1 collagen (2.8 mg/mL) in 0.5-mol/L acetic acid was mixed with
53 concentrated Dulbecco modified Eagle medium in purified water and buffered to a final pH of approximately 7.5,
as indicated by phenol red, with the use of sodium bicarbonate; the volume was adjusted to a final concentration of
1 mg/mL with deionized water before incubation. Type 1 collagen gels were cast from 300-µL volumes of cold 1 mg/mL
into 15 3 5-mm rectangular forms. Gels containing human
recombinant IGF-1 and/or IGF-2 were created by adding 3
µg of IGF-1 and/or IGF-2 (Upstate Biotechnology Inc, Lake
Placid, NY) in 0.5-mol/L acetic acid before the sodium bicarbonate was added. The doses of IGFs were based on hypothetical local distribution of IGFs, assuming equal distribution through a 500-g rat, using doses equivalent to those
showing skeletal effects when delivered by osmotic infusion pumps in studies by Thaller et al.7

lating with smaller volume units. Because these units of
volume negatively correlate with radiopacity, we have designated these volume units as radiodensitometric values; therefore, smaller radiodensitometric values are obtained with greater bone healing.8 Radiodensitometric
values obtained from ImageQuant analysis of the x-ray
films are presented in the Table. The mean (±SEM) for
the collagen-only group was 5593.5 ± 61.9; the mean for
the IGF-1 augmented group was 5175.0 ± 104.9. The mean
for the IGF-2–augmented group was 4451.3 ± 87.3. The
mean for the combination IGF-1 and IGF-2 group was
4826.2 ± 77.7. For comparison, a defect from a rat that
was killed immediately after surgery yielded a value of
6128. A nasal bone harvested from a rat with no surgical defect yielded a value of 2880. Statistically significant differences were shown between paired groups by
the Student t test.
Radiodensitometric measurements showed that the
IGF-2 augmentation resulted in greatest osseous healing, with measurements being statistically significant over
that of unaugmented gels (P,.001), IGF-1 augmentation (P,.001), and combination IGF-1 and IGF-2 augmentation (P#.003). Combination IGF-1 and IGF-2 had
osseous healing that was intermediate between IGF-1 augmentation and IGF-2 augmentation alone, with measurements being statistically significant over those of unaugmented gels (P,.001) and IGF-1 augmentation
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Radiodensitometric Values of X-rayed Nasal Defects*
No
Defect

No
Healing

2880

6128

Collagen

Collagen +
IGF-1

Collagen +
IGF-2

Collagen +
IGF-1 and -2

5423
5528
5730
5741
5711
5428
5593.5 ± 61.9†

5287
5339
5363
4695
5071
5295
5175.0 ± 104.9†

4392
4198
4766
4275
4425
4652
4451.3 ± 87.3†

4678
4662
4896
4643
5079
4999
4826.2 ± 77.7†

*IGF indicates insulinlike growth factor.
†Mean ± SEM.

COMMENT
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Defect treated with collagen augmented with combination insulinlike growth
factor (IGF) 1 and IGF-2 at 310 (A) and 340 (B) magnification; collagen
augmented with IGF-2 at 310 (C) and 340 (D) magnification; collagen only
at 310 (E) and 340 (F) magnification; and collagen augmented with IGF-1 at
310 (G) and 340 (H) magnification (hematoxylin-eosin). Arrows represent
the nasal septum; arrowheads, new bone growth.

(P#.03). Augmentation with IGF-1 resulted in healing
that was significant over that of unaugmented gels
(P#.04).
Histological examination of all groups showed
complete surface coverage with a thin layer of immature
bone. Visual comparison of bone thicknesses seen on
histological examination (Figure) appeared to correlate
with the radiodensitometric analysis (IGF2.combination IGF-1 and IGF-2.IGF-1.collagen
only). No evidence of inflammatory reactions was
apparent histologically.

Augmentation of T1CG with IGF resulted in osseous healing that was significant over that of unaugmented collagen gels. Augmentation with IGF-2 resulted in greatest
osseous healing, with measurements being statistically
significant over those of unaugmented gels (P,.001),
IGF-1 augmentation (P,.001), and combination IGF-1
and IGF-2 augmentation (P#.003). Combination IGF-1
and IGF-2 had osseous healing that was intermediate between IGF-1 augmentation and IGF-2 augmentation
alone, with measurements being statistically significant
over those of unaugmented gels (P,.001) and IGF-1 augmentation (P#.03). Augmentation with IGF-1 resulted
in healing that was significant over that of unaugmented gels (P#.04).
The technique of radiodensitometric analysis was
used in this and 1 other previous study for estimating
bone regeneration.8 Other techniques were considered.
Nuclear scanning for bone density is used for estimating large defect densities but is impractical for analyzing these small defect densities. Computed tomographic scans were used in our original study on type 1
collagen–mediated repair of nasal defects but were not
used in this study because of limitations with defects less
than 3 mm in depth.6 The use of ultrasound in estimating bone density has been used by other investigators but
is unavailable at our institution. In any study, analyzing
bone density and regeneration is a potential weakness.
We believe that this roentgenographic technique provides a good way to compare bone densities, particularly when used to compare radiodensities between flat
bones such as the nasalis, which is more suitable for this
technique than more complex-shaped bones. This method
of analysis does not give a direct value of bone density,
but the planar geometry of the excised dorsum does allow the 2-dimensional roentgenographic projections to
be used for the comparison of healing between groups.
It has previously been shown that untreated nasal
CSDs had less than 7% surface area healing during a 6week time span, while repair with the use of unaugmented type 1 collagen resulted in 100% surface area healing. 6 Type 1 collagen is a major component of the
extracellular matrix of bone. By laying down the 3dimensional T1CG into the defect, the major component
of the extracellular matrix is provided. A possible mechanism of increased healing, therefore, could be that the gel
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provides a scaffold for osteoblast migration.6 The addition of IGF-1 and IGF-2 confers additional osteoinductive properties and promotes healing of bone that is significantly greater than that of collagen gels alone. The use
of IGF-1– and IGF-2–augmented T1CG offers advantages over currently used techniques in nasal reconstruction. Because the type 1 collagen used in the gels is part
of the extracellular matrix of bone, it is readily incorporated into the healing defect and does not have the potential for extrusion at a later time. Many of the current techniques used in facial reconstruction possess notable risks
of infection. This study and previous studies using T1CGs
showed no signs of infection or inflammation.6,10
The increased healing with locally delivered IGF-1
and IGF-2 augmentation was not unexpected. Systemically released IGF-1 is believed to mediate the effects of
growth hormone by stimulating synthesis of glycogen in
the liver and the synthesis of collagen in bones.11 During the development of children, growth hormone is believed to play a key role in the growth of long bone; the
effects of growth hormone on bone growth are believed
to be mediated by IGF-1 production.12 Rats with calvarial CSDs that were administered IGF-1 with 14-day
osmotic infusion pumps showed nearly complete healing after 6 weeks, while control rats showed nearly no
healing after 8 weeks.7 Both IGF-1 and IGF-2 have been
shown to stimulate cell proliferation and collagen synthesis by osteoblasts as well as the synthesis of DNA, collagen, and noncollagen proteins in cultured rat calvaria.11 In addition, IGF-1 and IGF-2 have been shown
to decrease collagenase transcripts by more than 80% and
thus decrease collagen breakdown.13 While IGF-1 and
IGF-2 are circulating hormones and can act systemically, local production of IGF-1 and IGF-2 by skeletal
tissue is also an important source of these factors and may
act as a paracrine or autocrine regulator of bone formation. In fact, it has been postulated that systemic circulating IGF-1 mediates some of its actions at the growth
plates by stimulating the local production of IGF-1.14
The degrees to which IGF-1 and IGF-2 stimulate cell
proliferation and collagen synthesis and suppress collagenase production in vitro are roughly equivalent, hence
their in vitro efficacies appear to be comparable. Yet IGF-1
appears to be more potent than IGF-2, because it mediates these effects at lower molar concentrations. There
are 2 known types of IGF receptors, type 1 and type 2,
and both IGF-1 and IGF-2 interact with both types of receptors. In vitro evidence suggests that the stimulatory
effects of both IGF-1 and IGF-2 on isolated bone and bone
cell cultures are mediated by the type 1 receptors. Thus,
it has been proposed that the lower biological potency
displayed by IGF-2 in isolated bone and bone cell cultures results from the preference of the type 1 IGF receptor for binding IGF-1.14
In the rodent nasal CSD model, however, IGF-2–
augmented collagen gels resulted in bone healing that was
significantly greater than that of IGF-1–augmented collagen gels. This suggests that, in vivo, IGF-2 may have greater
efficacy than IGF-1 in mediating the repair of osseous nasal defects in rats. Several possibilities may explain this surprising result. First, the effects of IGFs are strongly influenced by the balance of IGFs, IGF receptors, and IGF-

binding proteins.15 The in vitro and in vivo environments
may cause cells to differ in the levels of expression of these
proteins. Second, studies have shown that bones and bone
cells taken from different parts of an organism have large
differences in the local expression of IGFs, IGF-binding
proteins, fibroblast growth factor, and alkaline phosphatase.16,17 No study to date has compared cells from the nasalis bone with those of other sites. Third, IGF-1 and IGF-2
messenger RNA is normally preferentially expressed at different times during fracture repair and growth. For example, endothelial and mesenchymal cells at the granulation tissue stage express a predominance of IGF-2
messenger RNA. At the stage of bone and cartilage formation, osteoblasts and nonhypertrophic chondrocytes express messenger RNA for both IGF-1 and IGF-2. Osteoclasts are positive for IGF-2 messenger RNA at the stage
of bone remodeling. In all stages, there is a predominance of IGF-2 in the human bone matrix.18
Most surprising of all was that augmentation of the
gels with a combination of both IGF-1 and IGF-2 resulted in healing that was intermediate between that of
IGF-1 augmentation and IGF-2 augmentation alone. There
was twice as much total IGF present in these gels (6 µg
total). The observed healing suggests that some inhibition of IGF-2 by IGF-1 might be explained if both factors act through the same receptors, as the 2 factors would
compete for the same receptor binding sites. In vitro evidence does suggest that both IGFs interact at the same
receptors but with different affinities. Another possible
explanation is a biphasic response. With this type of response, increasing concentrations of the growth factor
may increase growth at low concentrations, but, with
greater concentrations, decreased healing may result. This
type of dose-response activity is seen with transforming
growth factor-b.19
An advantage of using IGF-augmented collagen gels
over systemic delivery of IGFs is that the growth factors
are directed to the site of the defect. This provides a more
controlled dosage to the site, reduces the amount of IGFs
needed, and reduces the effects of high doses of systemic IGFs. Unlike the cranial vault, the nasalis bone forms
by endochondral ossification rather than intramembranous ossification. This is the first study, to our knowledge, to look at the effects of a known concentration of
IGF-2 delivered locally to a CSD in a site formed by endochondral ossification. The techniques to evaluate IGF-2
in higher animals exist, and the materials are currently
available for such studies. The use of IGF-2 is approved
in humans, and techniques for obtaining human collagen from amnions have been developed.20
CONCLUSIONS

Rat nasal defects treated with IGF-2–augmented T1CGs
showed healing that was significantly greater than that of
collagen only, IGF-1 augmentation, and combination IGF-1
and IGF-2 augmentation. Rat nasal defects treated with
combination IGF-1– and IGF-2–augmented T1CGs showed
healing that was intermediate between that of IGF-1 augmentation alone and IGF-2 augmentation alone, being significant over that of IGF-1 augmentation alone and collagen-only treatment. Rat nasal defects treated with IGF-
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1–augmented collagen gels showed healing that was
significant over that in rats treated with nonaugmented collagen gels. The use of IGF-augmented collagen gels in the
repair of nasal defects merits further investigation.
Accepted for publication August 26, 1998.
Presented at the Seventh International Symposium on
Facial Plastic Surgery, Orlando, Fla, June 18, 1998.
Reprints: William H. Lindsey, MD, Suite 302, Medical Office Bldg, Augusta Medical Center, 93 Medical Center Dr, Fishersville, VA 22939 (e-mail: whl5r@virginia.edu).
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